Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis

Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)

“…The percentage of patients with HbA1c <7% or weight loss ≥10% is similar to that in other real‐world data studies with subcutaneous semaglutide, such as the Marzullo et al study, SPARE trial, and SURE post‐hoc pooled analysis 12–14 . The safety profile in our study was consistent with that in previous reports 15 . Our discontinuation rates with oral semaglutide were similar to those in retrospective studies with subcutaneous semaglutide 12,13 and higher than those in pooled prospective SURE studies 14 …”

“…[12][13][14] The safety profile in our study was consistent with that in previous reports. 15 Our discontinuation rates with oral semaglutide were similar to those in retrospective studies with subcutaneous semaglutide 12,13 and higher than those in pooled prospective SURE studies. 14 Our findings highlight the associations among the high initial weight of the patient, endocrinology prescriptions and ongoing oral semaglutide use at 6 months.…”

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention

“… 58 According to the systematic review and meta-analysis of clinical trials, semaglutide treatment did have frequent gastrointestinal events like diarrhea. 59 The current study may show the correlation between this side effect caused by semaglutide and the increased abundance of the phylum Campylobacterota. Iqbal et al investigated the weight-loss effect of GLP-1 RAs in clinical patients with obesity but without diabetes.…”

Therapy of Type 2 Diabetes

“…Compared to other antidiabetic drugs, semaglutide resulted in a reduction in HbA1c of 0.26 % (95 % CI, 0.15-0.38) and 0.38 % (95 % CI, 0.31-0.45) respectively. The higher dosage of semaglutide (14 mg) did not increase the incidence of discontinuation of medication due to gastrointestinal adverse reactions [297].…”